Petrovax to Supply 13.3 Million Doses of Flu Vaccine to Russian Regions

g+sp-npo-box1-12s.jpgNPO Petrovax Pharm has completed the first phase of Grippol® Plus vaccine distribution for the flu vaccination of Russian children for the 2013–2014 flu season. The company has distributed more than 5 million doses of vaccine to 41 regions of Russia, in accordance with the National Vaccination Calendar of the Federal Flu Immunisation Programme.

This year, Petrovax started to ship the vaccine in August to ensure early children immunisation. The vaccine was first shipped to the regions affected by flooding in the Far Eastern Federal District: the Jewish Autonomous Region, Khabarovsk Territory, and Amur Region.

All Russian regions will receive the required amounts of Grippol® Plus (a total of 13.3 million doses) before mid-November 2013.

“We have been supplying regions with flu vaccine for children immunisation for five years now. It is a tremendous honour and a great social responsibility for our company. We are proud that Grippol® Plus is produced at one of most advanced high-tech pharmaceutical facilities in the country. The quality of our products is guaranteed as they are fully compliant with national and international standards. We are seeking to improve the health of people, and our main task is to provide them with a modern Russian-made medicine that offers high quality, effectiveness, and safety”, said Arkady Nekrasov, General Director of NPO Petrovax Pharm.

About Grippol® Plus
Grippol® Plus is a Russian-made, new-generation, inactivated influenza vaccine. As it is preservative-free and has proven effective and safe, Grippol® Plus can be widely used in adults and children, including infants from 6 months and individuals with chronic somatic diseases, e.g. cardiovascular diseases, allergies, and immunodeficiency disorders of different etiologies. The vaccine contains purified antigens for relevant influenza virus strains, selected in accordance with WHO recommendations for the current flu season. It is provided in single-dose syringes and is produced at a state-of-art facility in full compliance with the applicable international standards (GMP).

Previous news

Russia’s Ministry of Healthcare Readily Responds to RSPP President’s Request